98 related articles for article (PubMed ID: 26652977)
21. [Combined antineoplastic agents guidelines--guidelines for clinical trials I/II].
Gan To Kagaku Ryoho; 2004 Apr; 31(4):657-65. PubMed ID: 15114719
[No Abstract] [Full Text] [Related]
22. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
23. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
24. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
Sledge GW
Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
[TBL] [Abstract][Full Text] [Related]
25. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
26. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
27. Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package.
Cabarrou B; Sfumato P; Leconte E; Boher JM; Filleron T
Comput Biol Med; 2018 Sep; 100():239-246. PubMed ID: 30055524
[TBL] [Abstract][Full Text] [Related]
28. Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations.
Whitehead J; Thygesen H; Whitehead A
Stat Med; 2011 Jul; 30(16):1952-70. PubMed ID: 21590794
[TBL] [Abstract][Full Text] [Related]
29. Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'.
Riviere MK; Zohar S
Stat Med; 2016 Feb; 35(3):475-8. PubMed ID: 26757957
[No Abstract] [Full Text] [Related]
30. A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.
Dejardin D; Lesaffre E; Hamberg P; Verweij J
Pharm Stat; 2014; 13(3):196-207. PubMed ID: 24715683
[TBL] [Abstract][Full Text] [Related]
31. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
34. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
35. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
36. A two-dimensional biased coin design for dual-agent dose-finding trials.
Sun Z; Braun TM
Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
[TBL] [Abstract][Full Text] [Related]
37. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
Weiss MA
Semin Oncol; 2000 Apr; 27(2 Suppl 5):41-3. PubMed ID: 10877051
[TBL] [Abstract][Full Text] [Related]
38. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
39. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
40. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
DiƩras V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]